These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30922877)

  • 1. Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations.
    Pacheco JM; Camidge DR
    Lancet Respir Med; 2019 May; 7(5):366-367. PubMed ID: 30922877
    [No Abstract]   [Full Text] [Related]  

  • 2. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
    Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K
    Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol.
    Kitagawa C; Kada A; Saito AM; Ichinose Y; Saka H
    Kurume Med J; 2019 May; 65(2):77-81. PubMed ID: 30429415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor inhibition and non-small cell lung cancer.
    von Eyben FE
    Crit Rev Clin Lab Sci; 2006; 43(4):291-323. PubMed ID: 16769595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab in non-small cell lung cancer.
    Ademuyiwa FO; Hanna N
    Expert Opin Biol Ther; 2008 Jan; 8(1):107-13. PubMed ID: 18081540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.
    Tamiya M; Tamiya A; Shiroyama T; Takeoka S; Naito Y; Omachi N; Kimura Y; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
    Invest New Drugs; 2018 Aug; 36(4):608-614. PubMed ID: 29101518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-mutations in EGFR driven non-small cell lung cancer.
    Rosell R; Karachaliou N
    EBioMedicine; 2019 Apr; 42():18-19. PubMed ID: 30904603
    [No Abstract]   [Full Text] [Related]  

  • 11. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
    Hata A; Katakami N; Kaji R; Yokoyama T; Kaneda T; Tamiya M; Inoue T; Kimura H; Yano Y; Tamura D; Morita S; Negoro S; The Hanshin Oncology Group F
    Cancer; 2018 Oct; 124(19):3830-3838. PubMed ID: 30192383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
    Gridelli C; Maione P; Ferrara ML; Rossi A
    Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
    Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
    Takeda M; Nakagawa K
    Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T; Asahina H; Oizumi S; Yamada N; Harada M; Takamura K; Yokouchi H; Harada T; Honjo O; Ogi T; Morikawa N; Kinoshita I; Honda R; Nakano K; Kanazawa K; Amano T; Dosaka-Akita H; Isobe H; Nishimura M;
    Int J Clin Oncol; 2018 Dec; 23(6):1060-1069. PubMed ID: 30027464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer.
    Taniguchi Y; Takeda M; Tamiya A; Kasai T; Atagi S
    Ann Oncol; 2018 Nov; 29(11):2262-2263. PubMed ID: 30202942
    [No Abstract]   [Full Text] [Related]  

  • 18. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
    Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
    Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
    [No Abstract]   [Full Text] [Related]  

  • 19. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC).
    Kollmannsberger C; Schittenhelm M; Honecker F; Tillner J; Weber D; Oechsle K; Kanz L; Bokemeyer C
    Ann Oncol; 2006 Jun; 17(6):1007-13. PubMed ID: 16533873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.